Tirzepatide 10mg | NeuroPept Labs

Description

Tirzepatide (LY3298176), also listed as GLP-TZ or GLP-2TZ, is a synthetic 39-amino acid research peptide characterised as a dual GIP and GLP-1 receptor agonist — a molecular class termed “twincretin” — engineered to engage both the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) through a single peptide backbone. This bispecific receptor engagement distinguishes it from monoagonist GLP-1 compounds in incretin receptor pharmacology research.

NeuroPept Labs supplies Tirzepatide 10mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are manufactured under controlled synthesis conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

Tirzepatide’s molecular design is based on the native GIP sequence, with modifications enabling GLP-1R co-agonism and a C20 fatty diacid moiety studied for albumin binding and extended plasma residence in the published literature. Receptor-level properties characterised in vitro include:

• GIP Receptor (GIPR) — incretin receptor coupled to Gs signalling; GIPR is highly expressed in white adipose tissue, and Tirzepatide’s GIPR agonism is studied in adipocyte lipid-handling and adipokine-signalling models.
• GLP-1 Receptor (GLP-1R), biased agonism — in receptor-signalling assays Tirzepatide preferentially activates cAMP/Gs over β-arrestin recruitment, a property that differentiates it from native GLP-1 at the receptor level and is an active subject of in vitro pharmacology research.
• Dual-receptor co-activation — engagement of GIPR and GLP-1R through one molecule is studied in cell-based assays characterising combined incretin receptor signalling and cross-talk.

Receptor binding affinities and functional potency data are reported in the peer-reviewed sources cited below.

Tirzepatide vs Semaglutide vs Retatrutide

The three most-studied incretin-class research peptides differ in receptor profile:

NeuroPept Labs also supplies Retatrutide 10mg and Retatrutide 30mg for researchers studying the full spectrum of GLP-1/GIP/glucagon receptor agonism.

Research Significance

The material supplied by NeuroPept Labs is a research-use-only reference compound for in vitro laboratory work — it is not a pharmaceutical product and is not approved for human or veterinary use. Published areas of laboratory investigation include:

• Incretin biology and dual receptor (GIPR/GLP-1R) pharmacology
• Biased agonism characterisation at GLP-1R (cAMP/Gs vs β-arrestin)
• Beta-cell and pancreatic islet signalling models in vitro
• Adipocyte lipid-handling and adipokine signalling models
• Peptide structure–activity relationship studies
• Analytical method development and reference-standard characterisation

Tirzepatide 10mg Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles to preserve structural integrity
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using appropriate sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended research timeframes

Frequently Asked Questions

What is Tirzepatide (GLP-2TZ)?

Tirzepatide (LY3298176) is a synthetic 39-amino acid research peptide and dual GIP/GLP-1 receptor agonist — a molecular class termed “twincretin”. It is studied in vitro for dual incretin receptor pharmacology, biased agonism at GLP-1R, and peptide structure–activity relationships. It is also listed by some suppliers as GLP-TZ or GLP-2TZ.

What makes Tirzepatide a “biased agonist” at GLP-1R?

In receptor-signalling studies, Tirzepatide preferentially activates the cAMP/Gs pathway over β-arrestin recruitment at GLP-1R. This receptor-level property differentiates it from native GLP-1 and from other GLP-1R agonists and is an active area of in vitro pharmacology research.

How does Tirzepatide compare to Retatrutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide adds a third target, the glucagon receptor (GCGR), engaging hepatocyte-expressed receptor signalling not addressed by Tirzepatide’s dual profile. Both are available from NeuroPept Labs for comparative incretin receptor pharmacology research.

Is Tirzepatide supplied by NeuroPept Labs approved for human use?

No. The material supplied by NeuroPept Labs is a research-use-only reference compound for in vitro laboratory work. It is not a pharmaceutical product, is not the clinical product, and is not approved for human consumption, medical treatment, or veterinary use.

Where can I buy Tirzepatide research peptide?

Tirzepatide 10mg (GLP-2TZ) is supplied directly by NeuroPept Labs at neuropeptlabs.com for in vitro laboratory research use. Every vial ships with batch-specific Certificate of Analysis documentation, and material is supplied to qualified researchers and institutions only.

What purity is NeuroPept Labs’ Tirzepatide 10mg?

Our Tirzepatide 10mg research peptide is supplied at >99% purity, verified by HPLC and third-party analytical testing. COA documentation is available for every batch and can be verified at freedomdiagnosticstesting.com.

How do I verify the Certificate of Analysis?

Each batch is tested by an independent third-party laboratory. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code shown in the product images.

How should Tirzepatide 10mg be stored?

Store the lyophilized peptide at -20°C or below, away from direct light and moisture. Avoid repeated freeze-thaw cycles. Once reconstituted, store at 4°C and use within recommended laboratory timeframes.

Scientific References

1. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist — PMC / NIH 2020
2. Unveiling Tirzepatide’s Spectrum: A Dual GIP/GLP-1 Review — PMC / NIH 2025
3. Insights into the Mechanism of Action of Tirzepatide — PMC / NIH 2025